---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-122099"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2024-11-22T23:59:59+00:00"
generated_at: "2026-05-29T19:38:38.347986+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics gets Nasdaq deficiency for equity ($707K vs $2.5M min); also faces bid-price delisting risk

## Summary
- Stockholders' equity of $707,000 at Sep 30, 2024 is below Nasdaq's $2.5 million minimum.
- Company has 45 days (by Jan 3, 2025) to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- Also has outstanding minimum bid price deficiency; must close at $1.00+ for 10 consecutive days by Jan 27, 2025.
- Listing remains effective pending compliance; company evaluating options including reverse stock split.

## SEC filing metadata
- accession: 0001104659-24-122099
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2024-11-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465924122099/0001104659-24-122099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465924122099/tm2429290d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-122099
- JSON: https://secwatch.observer/filing/0001104659-24-122099.json
- Plain text: https://secwatch.observer/filing/0001104659-24-122099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.